Advanced search
Publication Cover
Current Medical Research and Opinion Volume 15, 1999 - Issue 4
Submit an article Journal homepage
114
Views
46
CrossRef citations to date
0
Altmetric
Research Article

A Long-term Study to Maximise Migraine Relief with Zolmitriptan

Stewart J. Tepper The Polyclinic, Seattle,, USA
,
Geoffrey A. Donnan Austin and Repatriation Medical Centre, Victoria, Australia
,
Andrew J. Dowson Neurology Headache Services, Kings College Hospital, UK
,
Martin A. M. Bomhof Ignatius Hospital, Breda, The Netherlands
,
Arthur Elkind Elkind Headache Center, New York, USA
,
Jacques Meloche Clinique de la Migraine de Montreal, Quebec, Canada
,
Pamela E. Fletcher Zeneca Pharmaceuticals, Wilrnington, USA
&
David S. Millson Zeneca Pharmaceuticals, Macclesfield, UK
 show all
Pages 254-271 | Published online: 26 Aug 2008

References

  • Goadsby P. J., Hoskin K. L. Inhibition of trigeminal neurones by intravenous administration of the serotonin (5HT) 1B/D agonist zolmitriptan (311C90): are brain stem sites therapeutic targets in migraine. Pain 1996; 67: 355–3591. Goadsby P. J., Hoskin K. L. Inhibition of trigeminal neurones by intravenous administration of the serotonin (5HT) 1B/D agonist zolmitriptan (311C90): are brain stem sites therapeutic targets in migraine. Pain 1996; 67: 355–359
  • Martin G. Pre-clinical pharmacology of zolmitriptan (Zomig™, formerly 311C90), a centrally and peripherally acting 5HTIB/ID agonist for migraine. Cephalalgia 1997; 17: 4–14, (Suppl 18)2. Martin G. Pre-clinical pharmacology of zolmitriptan (ZomigTM, formerly 311C90), a centrally and peripherally acting 5HTIB/ID agonist for migraine. Cephalalgia 1997; 17: 4–14, (Suppl 18)
  • Dixon R., Warrander A. The clinical pharmacokinetics of zolmitriptan. Cephalalgia 1997; 17: 15–20, (Suppl 18)3. Dixon R., Warrander A. The clinical pharmacokinetics of zolmitriptan. Cephalalgia 1997; 17: 15–20, (Suppl 18)
  • Rapoport A. M., Ramadan N. M., Adelman J. U., Mathew N. T., Elkind A. H., Kudrow D. B., Earl N. L. Optimising the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. Neurology 1997; 49: 1210–12184. Rapoport A. M., Ramadan N. M., Adelman J. U., Mathew N. T., Elkind A. H., Kudrow D. B., Earl N. L. Optimising the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. Neurology 1997; 49: 1210–1218
  • Schoenen J., Sawyer J. Zolmitriptan (Zomig™, 311C90), a novel dual central and peripheral 5HTIB/ID agonist: an overview of efficacy. Cephalalgia 1997; 17: 28–40, (Suppl 18)5. Schoenen J., Sawyer J. Zolmitriptan (ZomigTM, 311C90), a novel dual central and peripheral 5HTIB/ID agonist: an overview of efficacy. Cephalalgia 1997; 17: 28–40, (Suppl 18)
  • The International 311C90 Long-Term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (‘Zomig’, 311C90). An international study. Headache 1998; 38: 173–1836. The International 311C90 Long-Term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (‘Zomig’, 311C90). An international study. Headache 1998; 38: 173–183
  • Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8: 1–96, (Suppl 7)7. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8: 1–96, (Suppl 7)
  • Edmeads J., Millson D. S. Tolerability profile of zolmitriptan (Zomig™; 311C90), a novel dual central and peripheral 5HTIB/ID agonist. Cephalalgia 1997; 17: 41–52, (Suppl 18)8. Edmeads J., Millson D. S. Tolerability profile of zolmitriptan (ZomigTM; 311C90), a novel dual central and peripheral 5HTIB/ID agonist. Cephalalgia 1997; 17: 41–52, (Suppl 18)
  • Simmons V. E., Blakeborough P. The safety profile of sumatriptan. Reviews in Contemporary Pharmacotherapy 1994; 5: 319–3289. Simmons V. E., Blakeborough P. The safety profile of sumatriptan. Reviews in Contemporary Pharmacotherapy 1994; 5: 319–328

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.